AEterna Laboratories To Be Presenter at Tucker Anthony Sutro Health Care Conference 2001.Business Editors & Health/Medical Writers QUEBEC CITY, Quebec--(BW HealthWire)--April 2, 2001 Gilles Gagnon, Vice President, to Discuss Recent Breakthrough in Neovastat Clinical Trial Data In Prolonging Cancer Survival Times Gilles Gagnon, Vice President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of AEterna Laboratories Inc. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : AEL AEL Association Electronique Libre AEL Appalachia Educational Laboratory AEL Arabisch Europese Liga AEL Agence de l'Energie AEL Arab European League AEL Accessible Emission Limit AEL Acceptable Exposure Limit AEL Arquivo Edgard Leuenroth , NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AELA AELA Australian Environmental Labelling Association ) will be a presenter at the Tucker Anthony Sutro Health Care Conference 2001. Mr. Gagnon will deliver a company overview and data from a recent Phase I/II clinical trial that demonstrated a doubling of median survival time for patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. (kidney cancer) who were administered higher doses of Neovastat AE-941, AEterna's lead product. Mr. Gagnon will also discuss AEterna's strategy for growth through pharmaceutical partnerships and acquisitions. AEterna Laboratories Inc. is a Canadian biopharmaceutical company and a frontrunner in the field of antiangiogenesis to treat a variety of conditions. Neovastat, is an angiogenesis inhibitor being investigated in three major therapeutic areas: oncology, dermatology and ophthalmology. Mr. Gagnon commented on AEterna's participation in the conference, "We are honored to be included in a conference that is hosted by one of the leading financial companies in the healthcare industry. The timing is particularly fortunate since we have just announced such positive results from our Phase II Neovastat trials that demonstrate the effectiveness of our drug in increasing the survival time of certain cancer patients. We feel that this is the kind of breakthrough news in the war on cancer that other healthcare professionals and investors will find compelling and will want to hear more." The conference, scheduled for April 4-6 in Laguna Niguel, California Laguna Niguel is a city located in southern Orange County, California. The name "Laguna Niguel" is derived from the Spanish word "Laguna" which means lagoon and the word "Nigueli" which was the name of a Juaneno Indian village once located on Aliso Creek. , will include leading heathcare companies in the following industries: biotechnology, health care services, life science technology, medical devices and specialty pharmaceuticals. To arrange a one-on-one meeting with Gilles Gagnon, please contact Lisa Lindberg at The Investor Relations Group at (212)-736-2650 or theproteam@aol.com. Participation in the conference is limited to qualified investment professionals. Additional information about the conference is available from Susan Stone of Tucker Anthony Sutro at (310)315-8080 or sstone@sutro.com. AEterna is listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol AEL and on Nasdaq under the symbol AELA. News releases and additional information are available on its Web site at www.aeterna.com. Safe Harbor Statement This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of the business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's ongoing quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion